These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 18098337

  • 21. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.
    Int J Cancer; 2016 Mar 01; 138(5):1139-45. PubMed ID: 26376292
    [Abstract] [Full Text] [Related]

  • 22. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
    Minoo P, Moyer MP, Jass JR.
    J Pathol; 2007 Jun 01; 212(2):124-33. PubMed ID: 17427169
    [Abstract] [Full Text] [Related]

  • 23. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.
    Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C.
    Cancer Lett; 2009 Aug 28; 281(2):162-70. PubMed ID: 19344998
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y, Oki E, Nakanishi R, Ando K, Sugiyama M, Nakashima Y, Yamashita N, Saeki H, Oda Y, Maehara Y.
    J Cancer Res Clin Oncol; 2017 Jan 28; 143(1):151-160. PubMed ID: 27672042
    [Abstract] [Full Text] [Related]

  • 25. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
    Krol LC, 't Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE.
    Eur J Cancer; 2012 May 28; 48(7):1108-15. PubMed ID: 22446020
    [Abstract] [Full Text] [Related]

  • 26. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD, Lee JI, Lee IK, Oh ST, Jung ES, Lee SH.
    BMC Cancer; 2017 Jun 05; 17(1):403. PubMed ID: 28583095
    [Abstract] [Full Text] [Related]

  • 27. Somatic BRAF-V600E mutations in familial colorectal cancer.
    Vandrovcova J, Lagerstedt-Robinsson K, Påhlman L, Lindblom A.
    Cancer Epidemiol Biomarkers Prev; 2006 Nov 05; 15(11):2270-3. PubMed ID: 17119056
    [Abstract] [Full Text] [Related]

  • 28. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E, Kishani Farahani R, Mehrizi M, Baghaei K, Yaghoob Taleghani M, Golmohammadi M, Peyravian N, Ashtari S, Pourhoseingholi MA, Asadzadeh Aghdaei H, Zali MR.
    J Gastrointest Cancer; 2020 Mar 05; 51(1):53-62. PubMed ID: 30635874
    [Abstract] [Full Text] [Related]

  • 29. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T, Sakai D, Kawamoto K, Konno M, Nishida N, Koseki J, Colvin H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Satoh T, Doki Y, Mori M, Ishii H.
    Sci Rep; 2016 Jan 11; 6():18949. PubMed ID: 26750638
    [Abstract] [Full Text] [Related]

  • 30. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 11; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 31. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IeM.
    Cancer Res; 2005 Mar 01; 65(5):1994-2000. PubMed ID: 15753399
    [Abstract] [Full Text] [Related]

  • 32. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.
    Oncogene; 2018 Feb 08; 37(6):821-832. PubMed ID: 29059158
    [Abstract] [Full Text] [Related]

  • 33. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M, Hinoi T, Niitsu H, Miguchi M, Saito Y, Sada H, Sentani K, Sakamoto N, Oue N, Tashiro H, Sotomaru Y, Yasui W, Ohdan H.
    Cancer Sci; 2020 Oct 08; 111(10):3540-3549. PubMed ID: 32629543
    [Abstract] [Full Text] [Related]

  • 34. BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.
    Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L.
    Sci Signal; 2015 Apr 21; 8(373):ra38. PubMed ID: 25900832
    [Abstract] [Full Text] [Related]

  • 35. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
    Chan TL, Zhao W, Leung SY, Yuen ST, Cancer Genome Project.
    Cancer Res; 2003 Aug 15; 63(16):4878-81. PubMed ID: 12941809
    [Abstract] [Full Text] [Related]

  • 36. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.
    Int J Cancer; 2011 May 01; 128(9):2075-84. PubMed ID: 20635392
    [Abstract] [Full Text] [Related]

  • 37. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L.
    Anticancer Res; 2010 Sep 01; 30(9):3267-72. PubMed ID: 20944096
    [Abstract] [Full Text] [Related]

  • 38. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans.
    Rosenberg DW, Yang S, Pleau DC, Greenspan EJ, Stevens RG, Rajan TV, Heinen CD, Levine J, Zhou Y, O'Brien MJ.
    Cancer Res; 2007 Apr 15; 67(8):3551-4. PubMed ID: 17440063
    [Abstract] [Full Text] [Related]

  • 39. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
    Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, André T, Laurent-Puig P, Shi Q.
    Ann Oncol; 2023 Nov 15; 34(11):1025-1034. PubMed ID: 37619846
    [Abstract] [Full Text] [Related]

  • 40. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT, Böhm JP, Friman M, Lahtinen L, Väyrynen VM, Liipo TK, Ristimäki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP.
    Br J Cancer; 2015 Jun 09; 112(12):1966-75. PubMed ID: 25973534
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.